Add like
Add dislike
Add to saved papers

Sodium Glucose Co-Transporter 2 Inhibitors: Beyond Glucose Lowering.

Diabetes is an important cause of morbidity and mortality worldwide. Management of blood glucose is critical for diabetic patients since diabetes carries a risk for many diseases and disorders. Although there are several antidiabetic agents in the markets for a long time, some of the agents have dose-limiting side effects, such as hypoglycemia and weight gain which limits their ability to reduce cardiovascular complications. Sodium-glucose co-transporter 2 (SGLT2) inhibitors are a new class of antidiabetic agents which exerts their effects insulin-independent mechanism, therefore, they do not cause hypoglycemia in the diabetic patients. Due to the unique class-dependent mechanism, they can be adjunct to the standard therapy of the diabetic patients. Recent studies have speculated that SGLT2 inhibitors have some beneficial effects other than hypoglycemic effects in diabetic patients like lowering body weight, reducing blood pressure and hyperuricemia. This review aims to discuss the pleiotropic effects of SGLT2 inhibitors and gives an avenue for new research ideas.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app